Newscast – Page 182 – media

Merck pauses Keytruda studies to assess patient deaths

Merck has paused new enrolment in two studies assessing its immunotherapy Keytruda treatment in combination with other therapies in multiple myeloma to address safety concerns.
- Source: pharmatimes
- 488
- June 13, 2017
asthma Clinical Trials keytruda
Pioneering prostate biopsy device wins NIHR award

A new method for extracting prostate biopsies has been awarded a £789,000 Invention for Innovation (i4i) Product Development Award by the National Institute for Health Research (NIHR).
- Source: pharmatimes
- 524
- June 13, 2017
biopsy device Market Views NIHR
First PhIII trial of AbbVie’s upadacitinib a success

AbbVie’s upadacitinib has hit primary and secondary targets in the first late-stage trial of the drug involving patients with moderate-to-severe rheumatoid arthritis (RA).
- Source: Pharmatimes
- 524
- June 9, 2017
Clinical Trials rheumatoid arthritis
FDA approval granted to Emmaus for sickle cell therapy

Emmaus Medical recently received FDA (The U.S. Food and Drug Administration) approval for sickle cell disease therapy Endari (L-gluitamine), ending two decades of drought for treatment of the disease and giving an alternative to the only other drug on the market, hydroxyurea.
- Source: fiercebiotech
- 543
- June 9, 2017
Company Insight FDA therapy
Aspen Pharmacare hit by EU antitrust cancer drug price probe

Aspen Pharmacare is under investigation by the European Commission over its pricing practices for five cancer medicines.
- Source: pharmatimes
- 609
- May 16, 2017
cancer Company Insight EU
One in three RA patients rejecting meds because of cost

One in three people with rheumatoid arthritis in England are not taking their medicine as prescribed because of cost, according to The National Rheumatoid Arthritis Society (NRAS).
- Source: pharmatimes
- 540
- May 14, 2017
Market Views NRAS PPC
Second US approval for Merck, Pfizer’s Bavencio

Merck and Pfizer have announced a second accelerated approval in the US for Bavencio in less than two months, in this instance for certain patients with metastatic urothelial carcinoma.
- Source: pharmatimes
- 608
- May 10, 2017
cancer clinic Company Insight FDA gentic
Second US approval for Merck, Pfizer’s Bavencio

Merck and Pfizer have announced a second accelerated approval in the US for Bavencio in less than two months, in this instance for certain patients with metastatic urothelial carcinoma.
- Source: pharmatimes
- 592
- May 10, 2017
antibody Bavencio cancer New Approvals
GSK’s inhaler improves asthma control in ‘real world’ study

GlaxoSmithKline and Innoviva have unveiled data from a second ground-breaking Salford Lung Study (SLS) showing that Relvar Ellipta significantly improved asthma control versus patients’ standard therapy.
- Source: pharmatimes
- 592
- May 8, 2017
asthma Company Insight therapy
WHO improves transparency of financial data

WHO is improving transparency and accountability with the launch of a redesigned Programme Budget Web Portal that makes budget and spending information easier to access, use and understand.
- Source: pharmatimes
- 575
- May 4, 2017
IATI Market Views WHO

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.